336 related articles for article (PubMed ID: 25735995)
1. Dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia.
Takase M; Kanahara N; Oda Y; Kimura H; Watanabe H; Iyo M
J Psychopharmacol; 2015 Apr; 29(4):383-9. PubMed ID: 25735995
[TBL] [Abstract][Full Text] [Related]
2. The effectiveness of very slow switching to aripiprazole in schizophrenia patients with dopamine supersensitivity psychosis: a case series from an open study.
Kanahara N; Takase M; Sasaki T; Honma M; Fujita Y; Tadokoro S; Suzuki H; Yamanaka H; Noda S; Yanahashi S; Saiga T; Komatsu N; Simoyama T; Iyo M
Int Clin Psychopharmacol; 2020 Nov; 35(6):338-344. PubMed ID: 32868522
[TBL] [Abstract][Full Text] [Related]
3. Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice.
Nakata Y; Kanahara N; Iyo M
J Psychopharmacol; 2017 Dec; 31(12):1511-1518. PubMed ID: 28925317
[TBL] [Abstract][Full Text] [Related]
4. Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up.
Kimura H; Kanahara N; Sasaki T; Komatsu N; Ishige M; Muneoka K; Ino H; Yoshimura K; Yamanaka H; Suzuki T; Komatsu H; Watanabe H; Shimizu E; Iyo M
J Psychopharmacol; 2016 Aug; 30(8):795-802. PubMed ID: 27371496
[TBL] [Abstract][Full Text] [Related]
5. Case series on aripiprazole and dopamine supersensitivity psychosis.
Russell G; Reinfeld S; Kam O; Lee G; Weiss M; Koola MM
Int Clin Psychopharmacol; 2022 May; 37(3):122-128. PubMed ID: 35143441
[TBL] [Abstract][Full Text] [Related]
6. Can brexpiprazole be switched safely in patients with schizophrenia and dopamine supersensitivity psychosis? A retrospective analysis in a real-world clinical practice.
Yamasaki F; Kanahara N; Nakata Y; Koyoshi S; Yanagisawa Y; Saito T; Oiwa T; Kogure M; Sasaki T; Yoshida T; Kimura H; Iyo M
J Psychopharmacol; 2023 Oct; 37(10):992-1002. PubMed ID: 37395368
[TBL] [Abstract][Full Text] [Related]
7. Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial.
Takekita Y; Fabbri C; Kato M; Nonen S; Sakai S; Sunada N; Koshikawa Y; Wakeno M; Okugawa G; Kinoshita T; Serretti A
Eur Arch Psychiatry Clin Neurosci; 2015 Oct; 265(7):579-88. PubMed ID: 26016467
[TBL] [Abstract][Full Text] [Related]
8. Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia.
Suzuki T; Kanahara N; Yamanaka H; Takase M; Kimura H; Watanabe H; Iyo M
Psychiatry Res; 2015 Jun; 227(2-3):278-82. PubMed ID: 25863824
[TBL] [Abstract][Full Text] [Related]
9. Impact of dopamine supersensitivity psychosis in treatment-resistant schizophrenia: An analysis of multi-factors predicting long-term prognosis.
Yamanaka H; Kanahara N; Suzuki T; Takase M; Moriyama T; Watanabe H; Hirata T; Asano M; Iyo M
Schizophr Res; 2016 Feb; 170(2-3):252-8. PubMed ID: 26775264
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy.
Chouinard G; Samaha AN; Chouinard VA; Peretti CS; Kanahara N; Takase M; Iyo M
Psychother Psychosom; 2017; 86(4):189-219. PubMed ID: 28647739
[TBL] [Abstract][Full Text] [Related]
11. [Aripiprazole as dopamine partial agonist model: Basic concepts and clinical impact].
Simon N; Azorin JM
Encephale; 2018 Dec; 44(6):558-564. PubMed ID: 30466778
[TBL] [Abstract][Full Text] [Related]
12. Improvement or worsening of psychotic symptoms after treatment with low doses of aripiprazole.
Raja M
Int J Neuropsychopharmacol; 2007 Feb; 10(1):107-10. PubMed ID: 16487453
[TBL] [Abstract][Full Text] [Related]
13. Rationale and neurobiological effects of treatment with antipsychotics in patients with chronic schizophrenia considering dopamine supersensitivity.
Kimura H; Kanahara N; Iyo M
Behav Brain Res; 2021 Apr; 403():113126. PubMed ID: 33460681
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of clozapine on dopamine supersensitivity psychosis in schizophrenia.
Nakata Y; Kanahara N; Kimura H; Watanabe H; Iyo M
Int Clin Psychopharmacol; 2017 May; 32(3):169-173. PubMed ID: 28067751
[TBL] [Abstract][Full Text] [Related]
15. Can Aripiprazole Worsen Psychosis in Schizophrenia? A Meta-Analysis of Double-Blind, Randomized, Controlled Trials.
Takeuchi H; Fathi A; Thiyanavadivel S; Agid O; Remington G
J Clin Psychiatry; 2018; 79(2):. PubMed ID: 29570965
[TBL] [Abstract][Full Text] [Related]
16. Recent Discussions on Dopamine Supersensitivity Psychosis: Eight Points to Consider When Diagnosing Treatment-Resistant Schizophrenia.
Kanahara N; Kimura H; Oda Y; Ito F; Iyo M
Curr Neuropharmacol; 2021; 19(12):2214-2226. PubMed ID: 33550976
[TBL] [Abstract][Full Text] [Related]
17. Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis.
Tadokoro S; Okamura N; Sekine Y; Kanahara N; Hashimoto K; Iyo M
Schizophr Bull; 2012 Sep; 38(5):1012-20. PubMed ID: 21402722
[TBL] [Abstract][Full Text] [Related]
18. Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia.
Keks N; Hope J; Schwartz D; McLennan H; Copolov D; Meadows G
CNS Drugs; 2020 May; 34(5):473-507. PubMed ID: 32246399
[TBL] [Abstract][Full Text] [Related]
19. Switching antipsychotics to partial dopamine D2-agonists in individuals affected by schizophrenia: a narrative review.
Baumann P; Bauknecht P; Kuzin M; Schoretsanitis G
Int J Psychiatry Clin Pract; 2023 Nov; 27(4):367-384. PubMed ID: 37428441
[TBL] [Abstract][Full Text] [Related]
20. Alterations of Dopamine D2 Receptors and Related Receptor-Interacting Proteins in Schizophrenia: The Pivotal Position of Dopamine Supersensitivity Psychosis in Treatment-Resistant Schizophrenia.
Oda Y; Kanahara N; Iyo M
Int J Mol Sci; 2015 Dec; 16(12):30144-63. PubMed ID: 26694375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]